Global Blood Therapeutics Inc. priced its underwritten public offering of common stock for gross proceeds of about $100 million.
The company granted the underwriters an option to buy up an additional $15 million of common stock.
The offering is expected to close Dec. 19, subject to customary closing conditions.
Global Blood plans to use the net proceeds to fund the clinical development of voxelotor for treating sickle cell disease and other clinical trials. It also intends to use the net proceeds for other research and development activities, working capital, and general corporate purposes.
Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering.
